<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00823550</url>
  </required_header>
  <id_info>
    <org_study_id>4-2008-0296</org_study_id>
    <nct_id>NCT00823550</nct_id>
  </id_info>
  <brief_title>Antiviral Therapy in Hepatitis B Virus (HBV)-Related Advanced Liver Disease Patients</brief_title>
  <official_title>A Randomized, Open Label, Phase IV, Multicenter Study for Efficacy and Safety of Lamivudine Versus Entecarvir Therapy in HBV-related Advanced Liver Disease Patients With High Viral Load and Normal or Slightly Elevated Transaminase</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yonsei University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Severance Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Kangbuk Samsung Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Konkuk University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Chung-Ang University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ajou University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Inha University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Soonchunhyang University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Catholic University of Korea</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hallym University Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Kyungpook National University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Keimyung University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Korea University Anam Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Korea University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hanyang University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Inje University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Pusan National University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Yonsei University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, open label, phase IV, multicenter study for efficacy and safety of
      lamivudine versus entecarvir therapy in HBV-related advanced liver disease patients with high
      viral load and normal or slightly elevated transaminase.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Currently, treatment guidelines for the management of chronic hepatitis B (CHB) recommend
      that patients with serum HBV DNA &gt; 105 copies/ml and elevated ALT levels greater than two
      times the upper limit of normal (ULN) are obvious candidates for antiviral therapy.
      Guidelines also suggest that antiviral therapy be considered in CHB patients with high viral
      load, if a biopsy shows significant liver disease despite ALT ≤ 2× ULN. Data from recent
      trials in hepatitis B patients who present with normal to minimally elevated ALT (≤ 2× ULN)
      indicate that significant hepatic pathology could still be found. Serum ALT level may not
      accurately predict activity of liver damage. ALT is a poor predictor of outcome and therefore
      is not a suitable criterion for antiviral therapy in chronic hepatitis B infection. Also, a
      recent large randomized controlled clinical trial comparing lamivudine maintenance and
      placebo in advanced fibrosis (Ishak fibrosis score ≥ 4) suggests that sustained viral
      suppression with antiviral therapy is linked to reduced risk for disease progression. (Liaw
      YF et al. NEJM 2004;351:1521-1531)
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>January 2009</start_date>
  <completion_date type="Anticipated">July 2015</completion_date>
  <primary_completion_date type="Anticipated">July 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to disease progression as defined by the first occurrence of any of the cirrhosis compolications</measure>
    <time_frame>5 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients achieving either HBV DNA level ≤ 60 IU/mL Proportion of patients with ALT normalization Proportion of patients with HBeAg loss and seronconversion Proportion of patients with virologic breakthrough</measure>
    <time_frame>at months 12, 24, 36, 48, and 60</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">462</enrollment>
  <condition>Hepatitis B, Chronic</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>entecavir 0.5 mg QD</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>lamivudine 100 mg QD</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Entecavir</intervention_name>
    <description>entecavir 0.5 mg QD</description>
    <arm_group_label>A</arm_group_label>
    <other_name>Baraclude 0.5mg</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lamivudine</intervention_name>
    <description>lamivudine 100 mg QD</description>
    <arm_group_label>B</arm_group_label>
    <other_name>Zeffix 100mg</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria

          -  Male and female, 18 years of age or older

          -  HBsAg positive for more than 6 months

          -  Serum HBV DNA &gt; 2,000 IU/ml

          -  Serum ALT &lt; 2 X ULN on two consecutive occasions at least 3 months apart

          -  Naïve to nucleoside or nucleotide therapy

          -  On liver biopsy, fibrosis score ≥ 3 according to METAVIR scoring system (within 2
             years of Day 0)

          -  If liver biopsy is not available, subjects must have two of the following items

               -  Overt findings of cirrhosis by radiologic evidence (MRI, CT, US)

               -  Gastrointestinal varices

               -  Platelet count &lt; 100,000,Splenomegaly (Spleen size - 12cm)

          -  The patient who is willing and able to provide written informed consent to participate
             in this study

        Exclusion criteria

          -  A history of SBP, variceal bleeding, HEP, HCC

          -  Decompensated liver disease (Child-Pugh score &gt; 10)

          -  Co-infected with HCV or HIV

          -  History of any other forms of liver disease.

          -  Patient who is pregnant or breastfeeding

          -  Treatment with immunosuppressive, immunomodulatory agents or antiviral agents within 6
             months prior to study entry

          -  A history of liver transplantation or planned for liver transplantation

          -  A history of any other medical disease or condition that would make the patients
             unsuitable for the study.

          -  Patient is currently abusing alcohol or illicit drugs or has a history of alcohol
             abuse or illicit substance abuse within the preceding 2 years.

          -  Patient is enrolled or plans to enroll in another clinical trial of an investigational
             agent while participating in this study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kwnag-Hyub Han, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Yonsei Univsersity College of Medicine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jun Yong Park, MD</last_name>
    <role>Study Director</role>
    <affiliation>Yonsei Univsersity College of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Severance Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>January 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 14, 2009</study_first_submitted>
  <study_first_submitted_qc>January 14, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 15, 2009</study_first_posted>
  <last_update_submitted>December 15, 2010</last_update_submitted>
  <last_update_submitted_qc>December 15, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 16, 2010</last_update_posted>
  <responsible_party>
    <name_title>Kwang-Hyub Han</name_title>
    <organization>Department of Internal Medicine, Yonsei University College of Medicine</organization>
  </responsible_party>
  <keyword>Chronic hepatitis B</keyword>
  <keyword>Advanced fibrosis</keyword>
  <keyword>Lamivudine</keyword>
  <keyword>Entecavir</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Liver Diseases</mesh_term>
    <mesh_term>Hepatitis B, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lamivudine</mesh_term>
    <mesh_term>Entecavir</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

